TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ARVN

Arvinas Inc

Healthcare · Biotechnology

7.60$ -2.6% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow ARVN
Line item 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-290.9% 67.5% -112.5% -94.5% -411.7% 1,197.9% -208.1% -443.1% -98.4% -104.3%
6.5% 4.6% 4.9% 5.2% 18.5% 12.8% 6.2% 8.5% 2.5% 2.0%
7.9% 3.2% 81.2% 46.7% 138.5% 122.3% 57.5% 91.2% 33.5% 16.8%
0.8% 7.7% 82.5% 46.7% 136.9% 140.7% 57.5% – – –
-83.3% 372.3% 87.7% 16.7% -27.2% 1,452.5% -62.9% -56.6% -53.4% -89.0%
4.6% 13.4% 19.8% 14.5% 29.6% 10.1% 5.2% 3.7% 0.7% 0.7%
-301.6% 275.4% -1,254.3% -216.6% 753.4% -2,812.8% 184.8% 259.2% 13.2% 155.2%
– – 422.4% 8.0% – – – – – –
– – -23.9% -1.4% -134.1% 30.0% 3.6% 0.0% 0.0% -35.0%
-2.2% -2.1% 12.7% -0.4% – 0.0% 0.0% 0.0% -0.2% -0.1%
-2.2% -2.1% 1,173.3% 325.2% 2,314.8% 596.6% 3.6% 477.3% 3.0% -34.8%
-594.8% 340.7% -193.5% 14.0% 2,656.5% -1,018.4% -19.8% 293.5% -82.3% 16.1%
-295.5% 54.1% -132.3% -109.1% -441.3% 1,187.8% -213.3% -446.8% -99.1% -105.0%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?